A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT06876662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT06876662
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 279 participants
Conditions and interventions
Conditions
Interventions
- Pirtobrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2025
- Primary completion
- Apr 30, 2030
- Completion
- Nov 30, 2032
- Last update posted
- Mar 1, 2026
2025 – 2032
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136-1002 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232-6422 | Recruiting |
| The Emory Clinic | Atlanta | Georgia | 30322-1013 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611-3013 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
| Mayo Clinic- Minnesota | Rochester | Minnesota | 55905 | Recruiting |
| University Of Nebraska Medical Center | Omaha | Nebraska | 69198 | Recruiting |
| Cayuga Cancer Center | Ithaca | New York | 14850 | Active, not recruiting |
| Northwell Health | Lake Success | New York | 11042-1118 | Recruiting |
| Memorial Sloan-Kettering Cancer Center (MSKCC) - New York | New York | New York | 10065-6007 | Active, not recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710-4000 | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210-1063 | Recruiting |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203-2659 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4000 | Recruiting |
| Swedish Cancer Institute | Seattle | Washington | 98104-3588 | Recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226-3548 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06876662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2026 · Synced May 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06876662 live on ClinicalTrials.gov.